AVBP (ArriVent BioPharma) Liabilities-to-Assets : 0.06 (As of Dec. 2024)

ArriVent BioPharma Liabilities-to-Assets Chart

ArriVent BioPharma Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Liabilities-to-Assets	Get a 7-Day Free Trial						1.94	0.03	0.04	1.94	0.06

Competitive Comparison of ArriVent BioPharma's Liabilities-to-Assets

For the Biotechnology subindustry, ArriVent BioPharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArriVent BioPharma's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Liabilities-to-Assets falls into.

ArriVent BioPharma Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

ArriVent BioPharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

ArriVent BioPharma's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ArriVent BioPharma  (NAS:AVBP) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

ArriVent BioPharma Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description